Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010
Links shared publicly online about this topic.
- 1,083total visits
Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
View full resource at news-medical.net
Tags: Cystic Fibrosis, Clinical Trial, Gilead Sciences
Most Recently Shared on June 19, 2010 at 7:58 am By:
Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010: Gile... http://bit.ly/cRz93x
Advertisement
